ANSELMO PHARMA: what changed
Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
ANSELMO PHARMA
Largest movements
- Cash +€36,023
up €36,023 (+60.2%), from €59,803 to €95,826
mainly Net result for the year (+€62,258) and Tax, wage and social debts (+€23,584)
- Reserves +€61,425
up €61,425 (+63.6%), from €96,647 to €158,073
- Debts after one year -€49,579
down €49,579 (-7.0%), from €712,851 to €663,272
- Tax, wage and social debts +€23,584
up €23,584 (+76.8%), from €30,728 to €54,312
- Financial charges -€1,729
down €1,729 (-6.3%), from €27,342 to €25,613
- Gross operating margin +€1,184
up €1,184 (+1.1%), from €109,309 to €110,493
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €922,195 | €960,281 | +€38,086 | +4.1% |
| Fixed assets | 21/28 | €796,997 | €796,997 | = | 0.0% |
| Financial fixed assets | 28 | €796,997 | €796,997 | = | 0.0% |
| Current assets | 29/58 | €125,198 | €163,284 | +€38,086 | +30.4% |
| Amounts receivable within one year | 40/41 | €35,231 | €36,336 | +€1,105 | +3.1% |
| Other amounts receivable | 41 | €35,231 | €36,336 | +€1,105 | +3.1% |
| Current investments | 50/53 | €30,000 | €30,691 | +€691 | +2.3% |
| Cash at bank and in hand | 54/58 | €59,803 | €95,826 | +€36,023 | +60.2% |
| Deferred charges and accrued income | 490/1 | €165 | €431 | +€267 | +162.2% |
| Total equity and liabilities | 10/49 | €922,195 | €960,281 | +€38,086 | +4.1% |
| Equity | 10/15 | €121,647 | €183,073 | +€61,425 | +50.5% |
| Contributions | 10/11 | €25,000 | €25,000 | = | 0.0% |
| Reserves | 13 | €96,647 | €158,073 | +€61,425 | +63.6% |
| Distributable reserves | 133 | €96,647 | €158,073 | +€61,425 | +63.6% |
| Profit (loss) carried forward | 14 | - | €0 | = | |
| Amounts payable | 17/49 | €800,547 | €777,209 | -€23,339 | -2.9% |
| Amounts payable after more than one year | 17 | €712,851 | €663,272 | -€49,579 | -7.0% |
| Financial debts | 170/4 | €712,851 | €663,272 | -€49,579 | -7.0% |
| Amounts payable within one year | 42/48 | €78,485 | €104,724 | +€26,239 | +33.4% |
| Current portion of amounts payable after more than one year | 42 | €47,757 | €49,579 | +€1,822 | +3.8% |
| Trade debts | 44 | €0 | - | = | |
| Suppliers | 440/4 | €0 | - | = | |
| Taxes, remuneration and social security | 45 | €30,728 | €54,312 | +€23,584 | +76.8% |
| Taxes | 450/3 | €30,728 | €54,312 | +€23,584 | +76.8% |
| Other amounts payable | 47/48 | - | €833 | +€833 | |
| Accrued charges and deferred income | 492/3 | €9,211 | €9,212 | +€2 | 0.0% |
| Other operating charges | 640/8 | €203 | €208 | +€5 | +2.3% |
| Gross operating margin | 9900 | €109,309 | €110,493 | +€1,184 | +1.1% |
| Operating profit (loss) | 9901 | €109,106 | €110,285 | +€1,179 | +1.1% |
| Financial income | 75/76B | €1,252 | €1,317 | +€65 | +5.2% |
| Recurring financial income | 75 | €1,252 | €1,317 | +€65 | +5.2% |
| Financial charges | 65/66B | €27,342 | €25,613 | -€1,729 | -6.3% |
| Recurring financial charges | 65 | €27,342 | €25,613 | -€1,729 | -6.3% |
| Profit (loss) for the period before taxes | 9903 | €83,016 | €85,990 | +€2,974 | +3.6% |
| Income taxes | 67/77 | €22,898 | €23,732 | +€834 | +3.6% |
| Profit (loss) for the period | 9904 | €60,118 | €62,258 | +€2,140 | +3.6% |
| Profit (loss) for the period to be appropriated | 9905 | €60,118 | €62,258 | +€2,140 | +3.6% |
Source: filed annual accounts (NBB), fiscal years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 7 October 2026 via checked.be.